Survival analysis using UALCAN (Chandrashekar et al., 2017) shows that high expression of IDO-1 was often associated with worse prognosis (Supplementary Figure 1), such as in low-grade glioma, papillary renal cancer, pancreatic cancer, endometrial cancer, and uveal melanoma. Here, IDO1 is linked to central nervous system cancer.